JMP Securities analyst Jason Butler reiterated a Buy rating on Morphosys Ag (MOR – Research Report) today and set a price target of $17.00. The company’s shares opened today at $7.79.
Butler covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Cormedix, and ACADIA Pharmaceuticals. According to TipRanks, Butler has an average return of -7.1% and a 38.68% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Morphosys Ag with a $11.88 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $8.67 and a one-year low of $3.17. Currently, Morphosys Ag has an average volume of 199.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
Read More on MOR:
- MorphoSys upgraded to Hold from Sell at Deutsche Bank
- Biotech Alert: Searches spiking for these stocks today
- Wells Fargo Predicts up to 125% Rally for These 2 Stocks — Here’s Why They Have Solid Upside
- MorphoSys initiated with an Overweight at Wells Fargo
- MorphoSys upgraded to Overweight from Underweight at JPMorgan
